Lushang Freda PharmaceuticalLtd Résultats passés
Passé contrôle des critères 4/6
Lushang Freda PharmaceuticalLtd's earnings have been declining at an average annual rate of -22.5%, while the Real Estate industry saw earnings declining at 10.6% annually. Revenues have been declining at an average rate of 12% per year. Lushang Freda PharmaceuticalLtd's return on equity is 5.8%, and it has net margins of 5.9%.
Informations clés
-22.5%
Taux de croissance des bénéfices
-22.7%
Taux de croissance du BPA
| Real Estate Croissance de l'industrie | -5.2% |
| Taux de croissance des recettes | -12.0% |
| Rendement des fonds propres | 5.8% |
| Marge nette | 5.9% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares
Jun 21
Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Apr 16Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations
Mar 28Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Feb 27Ventilation des recettes et des dépenses
Comment Lushang Freda PharmaceuticalLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 3,986 | 237 | 1,593 | 157 |
| 30 Jun 24 | 4,031 | 240 | 1,643 | 154 |
| 31 Mar 24 | 4,197 | 233 | 1,686 | 156 |
| 31 Dec 23 | 4,579 | 303 | 1,704 | 153 |
| 30 Sep 23 | 7,817 | 130 | 1,741 | 155 |
| 30 Jun 23 | 10,590 | 47 | 1,711 | 144 |
| 31 Mar 23 | 12,741 | 108 | 1,685 | 141 |
| 31 Dec 22 | 12,951 | 45 | 1,677 | 134 |
| 30 Sep 22 | 14,543 | 13 | 1,750 | 117 |
| 30 Jun 22 | 13,131 | 240 | 1,788 | 123 |
| 31 Mar 22 | 12,140 | 342 | 1,708 | 118 |
| 31 Dec 21 | 12,363 | 362 | 1,638 | 119 |
| 30 Sep 21 | 12,929 | 729 | 1,568 | 111 |
| 30 Jun 21 | 14,137 | 710 | 1,431 | 100 |
| 31 Mar 21 | 13,915 | 662 | 1,307 | 88 |
| 31 Dec 20 | 13,615 | 639 | 1,169 | 77 |
| 30 Sep 20 | 10,316 | 572 | 1,029 | 68 |
| 30 Jun 20 | 9,817 | 482 | 986 | 62 |
| 31 Mar 20 | 10,307 | 364 | 980 | 53 |
| 31 Dec 19 | 10,289 | 345 | 1,033 | 46 |
| 30 Sep 19 | 10,373 | 222 | 979 | 32 |
| 30 Jun 19 | 10,159 | 195 | 949 | 30 |
| 31 Mar 19 | 9,261 | 184 | 875 | 30 |
| 31 Dec 18 | 8,821 | 162 | 823 | 30 |
| 30 Sep 18 | 10,105 | 166 | 1,093 | 47 |
| 30 Jun 18 | 8,694 | 159 | 961 | 37 |
| 31 Mar 18 | 8,476 | 129 | 868 | 30 |
| 31 Dec 17 | 8,287 | 128 | 753 | 24 |
| 30 Sep 17 | 7,576 | 102 | 296 | 0 |
| 30 Jun 17 | 7,909 | 98 | 306 | 0 |
| 31 Mar 17 | 7,370 | 94 | 308 | 0 |
| 31 Dec 16 | 7,646 | 92 | 316 | 0 |
| 30 Sep 16 | 7,151 | 107 | 337 | 0 |
| 30 Jun 16 | 5,870 | 101 | 329 | 0 |
| 31 Mar 16 | 6,118 | 103 | 332 | 0 |
| 31 Dec 15 | 5,864 | 112 | 324 | 0 |
| 30 Sep 15 | 5,109 | 166 | 336 | 0 |
| 30 Jun 15 | 6,365 | 205 | 325 | 0 |
| 31 Mar 15 | 5,908 | 207 | 330 | 0 |
| 31 Dec 14 | 5,682 | 206 | 334 | 0 |
| 30 Sep 14 | 6,387 | 287 | 344 | 0 |
| 30 Jun 14 | 5,790 | 273 | 372 | 0 |
| 31 Mar 14 | 5,477 | 272 | 353 | 0 |
| 31 Dec 13 | 5,293 | 263 | 344 | 0 |
Des revenus de qualité: 600223 has high quality earnings.
Augmentation de la marge bénéficiaire: 600223's current net profit margins (5.9%) are higher than last year (1.7%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 600223's earnings have declined by 22.5% per year over the past 5 years.
Accélération de la croissance: 600223's earnings growth over the past year (82.3%) exceeds its 5-year average (-22.5% per year).
Bénéfices par rapport au secteur d'activité: 600223 earnings growth over the past year (82.3%) exceeded the Real Estate industry -38%.
Rendement des fonds propres
ROE élevé: 600223's Return on Equity (5.8%) is considered low.